ATE358122T1 - Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen - Google Patents
Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungenInfo
- Publication number
- ATE358122T1 ATE358122T1 AT05290275T AT05290275T ATE358122T1 AT E358122 T1 ATE358122 T1 AT E358122T1 AT 05290275 T AT05290275 T AT 05290275T AT 05290275 T AT05290275 T AT 05290275T AT E358122 T1 ATE358122 T1 AT E358122T1
- Authority
- AT
- Austria
- Prior art keywords
- tnf
- autoimmune diseases
- inhibitors
- treatment
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000162945 | 2000-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE358122T1 true ATE358122T1 (de) | 2007-04-15 |
Family
ID=18666780
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06076696T ATE448204T1 (de) | 2000-05-31 | 2001-05-31 | 1-ä(adamantyl)alkylü-3- ä(pyridinyl)alkylüharnstoff-verbindungen als tnf- .alpha hemmer zur behandlung von autoimmunerkrankungen |
AT01934447T ATE374186T1 (de) | 2000-05-31 | 2001-05-31 | Tnf-alpha-produktions-inhibitoren |
AT05290275T ATE358122T1 (de) | 2000-05-31 | 2001-05-31 | Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen |
AT05290274T ATE481385T1 (de) | 2000-05-31 | 2001-05-31 | (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06076696T ATE448204T1 (de) | 2000-05-31 | 2001-05-31 | 1-ä(adamantyl)alkylü-3- ä(pyridinyl)alkylüharnstoff-verbindungen als tnf- .alpha hemmer zur behandlung von autoimmunerkrankungen |
AT01934447T ATE374186T1 (de) | 2000-05-31 | 2001-05-31 | Tnf-alpha-produktions-inhibitoren |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05290274T ATE481385T1 (de) | 2000-05-31 | 2001-05-31 | (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren |
Country Status (15)
Country | Link |
---|---|
US (5) | US7098226B2 (de) |
EP (4) | EP1302461B1 (de) |
JP (4) | JP3867196B2 (de) |
KR (2) | KR100978304B1 (de) |
CN (3) | CN1324012C (de) |
AT (4) | ATE448204T1 (de) |
AU (3) | AU6067401A (de) |
CA (2) | CA2409741C (de) |
CY (1) | CY1107089T1 (de) |
DE (4) | DE60140495D1 (de) |
DK (1) | DK1302461T3 (de) |
ES (4) | ES2293993T3 (de) |
NO (2) | NO324472B1 (de) |
PT (1) | PT1302461E (de) |
WO (1) | WO2001092229A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6067401A (en) * | 2000-05-31 | 2001-12-11 | Santen Pharmaceutical Co Ltd | Tnf-alpha production inhibitors |
US7741346B2 (en) * | 2001-11-30 | 2010-06-22 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
CN101404986B (zh) | 2002-05-17 | 2011-09-28 | 赛奎拉公司 | 用于诊断和治疗感染性疾病的组合物和制药方法 |
US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
WO2005034857A2 (en) | 2003-09-05 | 2005-04-21 | Sequella, Inc. | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
WO2005102332A1 (ja) * | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 変形性関節症治療剤 |
WO2005102331A1 (ja) * | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 骨粗鬆症治療剤 |
UA87854C2 (en) * | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
WO2006035760A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 皮膚疾患治療剤 |
WO2006035759A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
WO2006043518A1 (ja) * | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | 神経疾患治療剤 |
KR101302627B1 (ko) * | 2005-01-05 | 2013-09-10 | 아비에 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제 |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
BRPI0606256A2 (pt) * | 2005-01-05 | 2009-06-09 | Abbott Lab | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos |
US8562629B2 (en) * | 2006-10-24 | 2013-10-22 | Arthrocare Corporation | Suture device having selective needle actuation and related method |
EP1935420A1 (de) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren |
WO2009020603A2 (en) * | 2007-08-08 | 2009-02-12 | The Scripps Research Institute | Upp amphiphilic alpha-helix mimetics |
ES2431344T3 (es) * | 2007-10-16 | 2013-11-26 | Santen Pharmaceutical Co., Ltd | Agente terapéutico para la vejiga hiperactiva |
ES2528421T3 (es) * | 2008-10-22 | 2015-02-09 | Santen Pharmaceutical Co., Ltd | Composición farmacéutica de mejor absorción a través del tracto intestinal |
HRP20090186A2 (hr) | 2009-03-31 | 2010-10-31 | Institut Ruđer Bošković | Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona |
US8357939B2 (en) * | 2009-12-29 | 2013-01-22 | Siltronic Ag | Silicon wafer and production method therefor |
CN105934425B (zh) | 2013-11-15 | 2020-08-07 | 威斯塔解剖学和生物学研究所 | Ebna1抑制剂和其使用方法 |
SG11201708820TA (en) | 2015-05-14 | 2017-11-29 | Wistar Inst | Ebna1 inhibitors and methods using same |
TW201946919A (zh) | 2018-05-17 | 2019-12-16 | 威斯塔研究所 | Ebna1抑制劑晶形、其製備方法及其使用方法 |
CN110423216B (zh) * | 2019-08-26 | 2021-01-05 | 浙江工业大学 | 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用 |
WO2024084056A1 (en) * | 2022-10-21 | 2024-04-25 | Etherna Immunotherapies Nv | Ionizable lipids |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2640055A (en) * | 1951-01-06 | 1953-05-26 | Warner Hudnut Inc | Amides |
CH500979A (de) * | 1967-02-16 | 1970-12-31 | Shimamoto Takio | Verfahren zur Herstellung von Pyridinmethylcarbamaten |
US3682922A (en) * | 1969-01-16 | 1972-08-08 | Searle & Co | N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines |
US4597902A (en) | 1981-05-20 | 1986-07-01 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas |
US4724235A (en) | 1981-05-20 | 1988-02-09 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia |
US4555515A (en) * | 1985-02-25 | 1985-11-26 | Stauffer Chemical Co. | Pyridylpropyl carbamates as insect repellents |
US5599944A (en) * | 1987-03-24 | 1997-02-04 | Bayer Aktiengesellschaft | Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
FR2664269B1 (fr) | 1990-07-05 | 1992-10-02 | Roussel Uclaf | Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant. |
US5173506A (en) | 1990-08-16 | 1992-12-22 | Schering Corporation | N-(mercaptoalkyl)ureas and carbamates |
IE913855A1 (en) | 1990-11-06 | 1992-05-22 | Smithkline Beecham Corp | Imidazolidinone compounds |
NZ242054A (en) * | 1991-03-22 | 1993-11-25 | British Tech Group | Pyridine derivatives having a bridged alicyclic group; medicaments |
GB9401129D0 (en) | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
EP0757685B1 (de) * | 1994-04-29 | 2004-07-21 | Pfizer Inc. | Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung |
USRE39088E1 (en) * | 1995-08-22 | 2006-05-02 | Japan Tobacco, Inc. | Amide compounds and use of the same |
GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
GB9526558D0 (en) | 1995-12-27 | 1996-02-28 | Fujisawa Pharmaceutical Co | Heterobicyclic derivatives |
AU713676B2 (en) * | 1996-01-16 | 1999-12-09 | Merck & Co., Inc. | Integrin receptor antagonists |
IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
CA2275478A1 (en) * | 1996-12-17 | 1998-06-25 | Kentaro Sato | Piperazine compounds as inhibitors of mmp or tnf |
DE59806420D1 (de) | 1997-09-17 | 2003-01-09 | Chemiefaser Lenzing Ag | Verfahren zur Behandlung von Cellulosefasern |
EP0903434B1 (de) | 1997-09-17 | 2002-11-27 | Lenzing Aktiengesellschaft | Verfahren zur Behandlung von Cellulosefasern |
CA2325741C (en) | 1998-03-26 | 2007-05-08 | Santen Pharmaceutical Co., Ltd. | Urea derivatives having tnf- .alpha. production inhibitory effects |
JP3603177B2 (ja) | 1998-03-26 | 2004-12-22 | 参天製薬株式会社 | 新規ウレア誘導体 |
EP1103543A4 (de) | 1998-08-05 | 2005-06-22 | Santen Pharmaceutical Co Ltd | Harnstoffderivate mit stickstoffhaltigen aromatischen heterocyclen |
JP3472917B2 (ja) | 1998-08-05 | 2003-12-02 | 参天製薬株式会社 | 含窒素芳香族複素環を有する新規ウレア誘導体 |
EP1165531A1 (de) * | 1999-03-19 | 2002-01-02 | Du Pont Pharmaceuticals Company | N-adamant-1-yl-[4-chlorbenzothiazol-2-yl]harnstoff zur verwendung in der behandlung von entzündung und als antikrebs radiosensibilisierendes mittel |
KR20010112408A (ko) * | 1999-04-07 | 2001-12-20 | 모리타 다카카즈 | N-치환되고-N'-치환된 우레아 유도체 및 TNF-α 생성억제제로서의 그의 용도 |
DE29910780U1 (de) * | 1999-06-21 | 1999-09-16 | Hahn Schickard Ges | Halte- und Betätigungsvorrichtung |
AU6067401A (en) * | 2000-05-31 | 2001-12-11 | Santen Pharmaceutical Co Ltd | Tnf-alpha production inhibitors |
US7741346B2 (en) | 2001-11-30 | 2010-06-22 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
-
2001
- 2001-05-31 AU AU6067401A patent/AU6067401A/xx active Pending
- 2001-05-31 ES ES01934447T patent/ES2293993T3/es not_active Expired - Lifetime
- 2001-05-31 KR KR1020087023872A patent/KR100978304B1/ko not_active IP Right Cessation
- 2001-05-31 KR KR1020027016230A patent/KR100880698B1/ko not_active IP Right Cessation
- 2001-05-31 CA CA2409741A patent/CA2409741C/en not_active Expired - Fee Related
- 2001-05-31 EP EP01934447A patent/EP1302461B1/de not_active Expired - Lifetime
- 2001-05-31 DE DE60140495T patent/DE60140495D1/de not_active Expired - Lifetime
- 2001-05-31 ES ES05290274T patent/ES2353020T3/es not_active Expired - Lifetime
- 2001-05-31 DK DK01934447T patent/DK1302461T3/da active
- 2001-05-31 AT AT06076696T patent/ATE448204T1/de not_active IP Right Cessation
- 2001-05-31 EP EP05290274A patent/EP1568692B1/de not_active Expired - Lifetime
- 2001-05-31 PT PT01934447T patent/PT1302461E/pt unknown
- 2001-05-31 ES ES05290275T patent/ES2284138T3/es not_active Expired - Lifetime
- 2001-05-31 DE DE60143098T patent/DE60143098D1/de not_active Expired - Lifetime
- 2001-05-31 WO PCT/JP2001/004586 patent/WO2001092229A1/ja active IP Right Grant
- 2001-05-31 CN CNB200410054677XA patent/CN1324012C/zh not_active Expired - Fee Related
- 2001-05-31 DE DE60127595T patent/DE60127595T2/de not_active Expired - Lifetime
- 2001-05-31 AT AT01934447T patent/ATE374186T1/de active
- 2001-05-31 ES ES06076696T patent/ES2339141T3/es not_active Expired - Lifetime
- 2001-05-31 EP EP06076696A patent/EP1743885B1/de not_active Expired - Lifetime
- 2001-05-31 JP JP2001164523A patent/JP3867196B2/ja not_active Expired - Fee Related
- 2001-05-31 DE DE60130658T patent/DE60130658T2/de not_active Expired - Lifetime
- 2001-05-31 EP EP05290275A patent/EP1561749B1/de not_active Expired - Lifetime
- 2001-05-31 AT AT05290275T patent/ATE358122T1/de not_active IP Right Cessation
- 2001-05-31 CN CNB2004100546746A patent/CN1307159C/zh not_active Expired - Fee Related
- 2001-05-31 AT AT05290274T patent/ATE481385T1/de not_active IP Right Cessation
- 2001-05-31 CN CNB018102336A patent/CN1284771C/zh not_active Expired - Fee Related
- 2001-05-31 CA CA2736344A patent/CA2736344A1/en not_active Abandoned
- 2001-05-31 US US10/168,777 patent/US7098226B2/en not_active Expired - Fee Related
- 2001-05-31 AU AU2001260674A patent/AU2001260674B2/en not_active Ceased
-
2002
- 2002-11-28 NO NO20025718A patent/NO324472B1/no not_active IP Right Cessation
-
2006
- 2006-02-28 AU AU2006200864A patent/AU2006200864B2/en not_active Ceased
- 2006-05-19 JP JP2006140241A patent/JP4482735B2/ja not_active Expired - Fee Related
- 2006-06-07 US US11/448,634 patent/US7491739B2/en not_active Expired - Fee Related
- 2006-06-22 US US11/472,603 patent/US7345064B2/en not_active Expired - Fee Related
-
2007
- 2007-06-29 NO NO20073371A patent/NO20073371L/no not_active Application Discontinuation
- 2007-08-15 US US11/893,238 patent/US20080182881A1/en not_active Abandoned
- 2007-12-14 CY CY20071101588T patent/CY1107089T1/el unknown
-
2009
- 2009-09-23 US US12/586,515 patent/US7923461B2/en not_active Expired - Fee Related
- 2009-12-14 JP JP2009283085A patent/JP2010059205A/ja active Pending
- 2009-12-14 JP JP2009283084A patent/JP2010059204A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE358122T1 (de) | Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen | |
HUP0302943A2 (hu) | Új heterociklusos vegyületek, előállításuk és alkalmazásuk gyógyszerekként, különösen antibakteriális szerekként | |
ATE164575T1 (de) | Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer | |
ATE327230T1 (de) | Piperidinverbindungen und diese enthaltenden medikamente | |
WO1998003505A3 (en) | Heterocyclic compounds, their production and use | |
ATE339409T1 (de) | Trizyklische verbindungen | |
DE602004026629D1 (de) | Cyclopropanderivate und ihre pharmazeutische verwendung | |
MXPA02011417A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos. | |
NZ338016A (en) | Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same | |
MXPA02011418A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico. | |
NO20004092L (no) | Cyklisk amidforbindelse | |
TNSN99218A1 (fr) | Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant. | |
EP0567090A3 (de) | ||
EA200200611A1 (ru) | Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции | |
ATE99934T1 (de) | Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten. | |
EP1122252A4 (de) | Stickstoffhaltige annelierte heterocyclen, verfahren zu ihrer herstellung und agentien, die diese enthalten | |
ATE116650T1 (de) | Sulfonylamin substituierte bizyklische hydroxansäurederivate. | |
HUP0400207A2 (hu) | Helyettesített 4-amino-ciklohexanol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
ATE419238T1 (de) | Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz | |
CA2364199A1 (fr) | Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
DE69911373D1 (de) | Azetidincarboxamidderivate zur behandlung von zns-erkrankungen | |
ATE449760T1 (de) | Nichtpeptidinhibitoren von matrixmetalloproteinasen | |
ATE261940T1 (de) | Verfahren zur herstellung von n-alkenyl-amiden | |
ATE220665T1 (de) | Azetidincarboxamidderivate zur behandlung von zns-erkrankungen | |
DK1149079T3 (da) | Tetrahydroisoquinolinalkanolderivater og farmaceutiske præparater indeholdende samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |